Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study

Trial Profile

Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Salivary gland cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2017 Results published in the Cancer
    • 07 Jun 2016 This study has been stopped after an enrolment of 20 patients because no responder was observed at Stage I, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Status changed from active, no longer recruiting to discontinued, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top